3Danchin N,Charpentier G,Ledru F,et al.Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction:results from a nationwide French registry[J].Diabetes Metab Res Rev,2005,21(2):143-149.
4Zeller M,Danchin N,Simon D,et al.Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction[J].J Clin Endocrinol Metab,2010,95(11):4993-5002.
5Pi(n)ol C,Roze S,Valentine W,et al.Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain[J].Gac Sanit,2007,21(2):97.
6Scherbaum WA,Goodall G,Erny-Albrecht KM,et al.Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease:a German perspective[J].Cost Eff Resour Alloc,2009,5(7):9.
7Lee WC,Conner C,Hammer M.Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin,glimepiride,or both for the treatment of type 2 diabetes in the United States[J].Clin Ther,2010,32(10):1756.
8Sullivan SD,Alfonso-Cristancho R,Conner C,et al.A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus[J].Pharmacotherapy,2009,29(11):1280.
9Palmer JL,Beaudet A,White J,et al.Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China[J].Adv Ther,2010,27(11):814-827.
10Mourier A,Gautier,JF,De Kerviler E,et a1.Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM:effects of branchedchain amino acid supple-ments[J].Diabetes Care,2004,20(Suppl 4):385-391.
